Explanipedia

Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model Open

Alexis Steinmetz, M Pierce, Alberto Martini, Côme Tholomier, Ganiraju C. Manyam , et al. · 2024

Introduction Nadofaragene firadenovec (Ad-IFNα/Syn3) is now approved for BCG-unresponsive bladder cancer (BLCA). IFNα is a pleiotropic cytokine that causes direct tumor cell killing via TRAIL-mediated apoptosis, angiogenesis inhibition, an…

An in-depth analysis on the effects of body composition in patients receiving neoadjuvant chemotherapy for urothelial cell carcinoma Open

Landan MacDonald, Ricardo Rendon, Myuran Thana, Lori Wood, Robyn Jane Macfarlane , et al. · 2024

Introduction: Neoadjuvant chemotherapy (NAC) is the standard of care for patients undergoing radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC); however, NAC can be associated with significant side effects and morbidity in s…

Lentiviral interferon: A novel method for gene therapy in bladder cancer Open

Sharada Mokkapati, Vikram M. Narayan, Ganiraju C. Manyam, Amy Lim, Jonathan J. Duplisea , et al. · 2022

MP76-15 ORGAN SPARING SURGERY (OSS) FOR LOCALIZED PENILE CANCER: LONG-TERM RESULTS Open

Andrea Kokorovic, Jonathan J. Duplisea, Wei Qiao, Barrett Z. McCormick, Mehrad Adibi , et al. · 2020

You have accessJournal of UrologyPenile & Testicular Cancer: Penile & Testicular Cancer III (MP76)1 Apr 2020MP76-15 ORGAN SPARING SURGERY (OSS) FOR LOCALIZED PENILE CANCER: LONG-TERM RESULTS Andrea Kokorovic*, Jonathan Duplisea, Wei Qiao, …

PD42-08 NOVEL COMBINATION THERAPY USING LENTIVIRAL INTERFERON AND IMMUNE CHECKPOINT BLOCKADE FOR TREATMENT OF BLADDER CANCER IN A MURINE MODEL Open

Andrea Kokorovic, Sharada Mokkapati, Jonathan J. Duplisea, Devin Plote, Amy Lim , et al. · 2020

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology III (PD42)1 Apr 2020PD42-08 NOVEL COMBINATION THERAPY USING LENTIVIRAL INTERFERON AND IMMUNE CHECKPOINT BLOCKADE FOR TREATMENT OF BLADDER CANCER IN A MURINE …

Should chemotherapy still be used to treat all muscle invasive bladder cancer in the “era of immunotherapy”? Open

Jonathan J. Duplisea, Colin P. Dinney · 2019

Platinum-based chemotherapy has served as the mainstay systemic treatment for muscle invasive bladder cancer (MIBC) for decades. Its use in the neoadjuvant (NAC), adjuvant (AC), and salvage setting...

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer Open

Charles C. Guo, Tadeusz Majewski, Li Zhang, Hui Yao, Jolanta Bondaruk , et al. · 2019

Sarcomatoid urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARC and 84 cases of conventional urothelial ca…

Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma Open

Jonathan J. Duplisea, Firas G. Petros, Roger Li, Bryan Fellman, Charles C. Guo , et al. · 2019

The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside Open

Jonathan J. Duplisea, Sharada Mokkapati, Devin Plote, Kimberly S. Schluns, David J. McConkey , et al. · 2018

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer Open

Charles C. Guo, Tadeusz Majewski, Li Zhang, Hui Yao, Jolanta Bondaruk , et al. · 2018

SUMMARY The sarcomatoid variant of urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARCs and 84 cases of co…

Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma Open

Jonathan J. Duplisea, Ross Mason, Chad A. Reichard, Roger Li, Yu Shen , et al. · 2018

Introduction: Neoadjuvant chemotherapy (NAC) prior to radical or partial cystectomy is considered the standard of care for eligible patients with muscle-invasive urothelial carcinoma. Despite guideline recommendations, adoption of NAC has …

PD42-05 OUTCOMES OF SURGICAL MANAGEMENT OF LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS FROM THE PROSTATE CANCER CANADIAN COLLABORATION Open

Jesse Ory, Rodney H. Breau, Fred Saad, Wassim Kassouf, Bobby Shayegan , et al. · 2018

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy VI1 Apr 2018PD42-05 OUTCOMES OF SURGICAL MANAGEMENT OF LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS FROM THE PROSTATE CANCER CANADIAN COLLABORATION Jesse Ory, Ro…

MP47-14 THE UTILITY OF THE ACS NSQIP SURGICAL RISK CALCULATOR IN PATIENTS UNDERGOING RADICAL CYSTECTOMY: OPEN AND ROBOTIC TECHNIQUES Open

Jonathan J. Duplisea, Mohamed Seif, William Tabayoyong, Thomas A. Aloia, Shanna Pretzsch , et al. · 2018

You have accessJournal of UrologyBladder Cancer: Invasive IV1 Apr 2018MP47-14 THE UTILITY OF THE ACS NSQIP SURGICAL RISK CALCULATOR IN PATIENTS UNDERGOING RADICAL CYSTECTOMY: OPEN AND ROBOTIC TECHNIQUES Jonathan Duplisea, Mohamed Seif, Wil…

MP47-04 REFINING SELECTION CRITERIA FOR NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: COMBINING CLINICAL RISK FEATURES AND INTRINSIC MOLECULAR SUBTYPES Open

Jonathan J. Duplisea, Michael Metcalfe, Debasish Sundi, Jed Ferguson, Roger Li , et al. · 2018

You have accessJournal of UrologyBladder Cancer: Invasive IV1 Apr 2018MP47-04 REFINING SELECTION CRITERIA FOR NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: COMBINING CLINICAL RISK FEATURES AND INTRINSIC MOLECULA…

Jonathan J. Duplisea YOU? Author Swipe